Keratolytics are drugs that help remove excess skin ... Vtama is a cream that is approved to treat plaque psoriasis. It is applied to the affected area once a day in a thin layer.

The favorable data provided support for two ongoing phase III, randomized, placebo-controlled trials of ESK-001 in moderate/severe plaque psoriasis. Two TYK2 inhibitors developed in China also ...

Plaque psoriasis misdiagnosis is common in people of color. Learn the reasons why, how it can affect your health, and what you can do to get better care.

For Anthony, her plaque psoriasis has remained relatively the same since her diagnosis 10 years ago. "I haven't seen it get worse. I haven't seen it get better.

Icotrokinra achieved 75% complete skin clearance in adolescents with moderate to severe plaque psoriasis by week 24, indicating significant efficacy. The ICONIC-LEAD trial is the first to evaluate ...

Icotrokinra appears to be an effective treatment for adolescent patients with moderate to severe plaque psoriasis, according to a subgroup analysis of the ICONIC-LEAD study. The randomized ...

ORLANDO, Fla. — Adults with moderate to severe plaque psoriasis taking the novel oral drug icotrokinra had significant improvement starting at week 16, with increased response rates continuing ...

While nearly 8 million Americans live with plaque psoriasis, its impact is often unseen or covered up. 1 Art, whose music has touched millions worldwide, lived silently with his psoriasis—until now.

Obesity was linked to reduced long-term effectiveness of biologic therapy in patients with severe plaque psoriasis in a study, with dysregulated innate immune responses contributing to treatment ...

Opens in a new tab or window ORLANDO -- The TYK2 inhibitor deucravacitinib (Sotyktu) showed clinical potential in two diseases other than psoriasis, according to studies reported here. More than ...

The US FDA has approved a label extension for UCB’s Cimzia (certolizumab pegol) for adults with moderate-to-severe plaque psoriasis, marking the company’s entry into immuno-dermatology ...

Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with icotrokinra achieved completely clear skin (IGA 0) at Week 24 in Phase 3 ICONIC-LEAD study Topline results from ...